Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions

Bone Marrow Transplantation

Volumn 44, Issue 12, 2009, Pages 805-812

  Dvorak, C C ^a   Gilman, A L ^b   Horn, B ^a   Jaroscak, J ^c   Dunn, E A ^a   Baxter Lowe, L A ^d   Cowan, M J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Levine Children's Hospital   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Donor lymphocyte infusions; Haplocompatible; Hematopoietic SCT

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; MELPHALAN; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES VIRUS; HLA MATCHING; HUMAN; HYPOHIDROTIC ECTODERMAL DYSPLASIA; LYMPHOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL MOBILIZATION; T CELL DEPLETION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; BLOOD DONORS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE TRANSFUSION; MALE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 75049083710     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.87     Document Type: Article

References (32)

1. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
2. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
3. Dvorak C, Cowan M. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant 2008; 41: 119-126. (Pubitemid 351188908)
4. Smith F, Thomson B. T-cell recovery following marrow transplant: experience with delayed lymphocyte infusions to accelerate immune recovery or treat infectious problems. Pediatr Transplant 1999; 3 (Suppl 1): 59-64.
5. Loren A, Porter D. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol 2006; 18: 107-114.
6. Pati A, Godder K, Lamb L, Gee A, Henslee-Downey P. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995; 15: 979-981.
7. Godder K, Abhyankar S, Lamb L, Best R, Geier S, Pati A et al. Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant. Bone Marrow Transplant 1998; 22: 111-113.
8. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLAmismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777-783.
9. Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31: 39-44.
10. Kasow K, Leung W, Horwitz E, Woodard P, Handgretinger R, Hale G. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation. Pediatr Blood Cancer 2007; 49: 869-872.
11. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versushost disease. Blood 1995; 86: 4422-4429.
12. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value. Blood 2007; 110: 433-440.
13. Dvorak C, Hung G-Y, Horn B, Dunn E, Oon C-Y, Cowan M. Megadose CD34+ cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible non-myeloablative transplantation. Biol Blood Marrow Transplant 2008; 14: 1125-1133.
14. Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-765.
15. Sutherland D, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
18. Sinclair E, Black D, Epling C, Carvidi A, Josefowicz S, Bredt B et al. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol 2004; 17: 445-454.
19. Bao L, Sun Q, Lucas K. Rapid generation of CMV pp65- specific T cells for immunotherapy. J Immunother 2007; 30: 557-561.
20. Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E et al. Partially mismatched pediatric transplants with allogeneic CD34+ blood cells from a related donor. Blood 1998; 92: 3123-3130. (Pubitemid 28492318)
21. Reddy V, Hill G, Pan L, Gerbitz A, Teshima T, Brinson Y et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation 2000; 69: 691-693.
22. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1203.
23. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002; 100: 1192-1200.
24. Ferná ndez-Herrera J, Valks R, Feal C, Fraga J, Tomás J, Garcia-Díez A. Induction of hyperacute graft-vs-host disease after donor leukocyte infusions. Arch Dermatol 1999; 135: 304-308.
25. Kline R, Stiehm E, Cowan M. Bone marrow 'boosts' following T cell-depleted haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17: 543-548.
26. Chen X, Hale G, Barfield R, Benaim E, Leung W, Knowles J et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135: 524-532.
27. Eyrich M, Lang P, Lal S, Bader P, Handgretinger R, Klingebiel T et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen- disparate haematopoietic stem cells from parental donors. Br J Haematol 2001; 114: 422-432.
28. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-4406.
29. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia P. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother 2007; 30: 544-556.
30. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo M et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648-1655.
31. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130-137.
32. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108: 1797-1808.